[{"address1": "117, Avenue de Luminy", "address2": "BP 30191", "city": "Marseille", "zip": "13009", "country": "France", "phone": "33 4 30 30 30 30", "fax": "33 4 30 30 30 00", "website": "https://www.innate-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory s\u00e9zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.", "fullTimeEmployees": 174, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jonathan E. Dickinson B.Sc., M.B.A.", "age": 57, "title": "CEO & Director", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 133237, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yannis  Morel Ph.D.", "age": 52, "title": "Executive VP & COO", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 514142, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sonia  Quaratino M.D., Ph.D.", "age": 63, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 586849, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fran\u00e7ois  Romagn\u00e9 Ph.D.", "age": 61, "title": "Founder", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Bonneville Ph.D.", "age": 65, "title": "Founder", "yearBorn": 1960, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean Jacques Fourni\u00e9 Ph.D.", "title": "Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alessandro  Moretta M.D., Ph.D.", "title": "Founder", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederic  Lombard M.B.A.", "age": 50, "title": "Senior VP & CFO", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stephanie  Cornen", "title": "Vice President of Investor Relations, Communication & Commercial Strategy", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Odile  Belzunce", "age": 45, "title": "Vice President of Compliance, IT & Portfolio Management", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.77, "open": 1.8382, "dayLow": 1.78, "dayHigh": 1.89, "regularMarketPreviousClose": 1.77, "regularMarketOpen": 1.8382, "regularMarketDayLow": 1.78, "regularMarketDayHigh": 1.89, "payoutRatio": 0.0, "beta": 0.593, "forwardPE": -3.019802, "volume": 85809, "regularMarketVolume": 85809, "averageVolume": 203240, "averageVolume10days": 17470, "averageDailyVolume10Day": 17470, "bid": 1.86, "ask": 1.94, "bidSize": 1, "askSize": 1, "marketCap": 171481184, "fiftyTwoWeekLow": 1.63, "fiftyTwoWeekHigh": 2.63, "allTimeHigh": 11.95, "allTimeLow": 1.29, "priceToSalesTrailing12Months": 13.570844, "fiftyDayAverage": 1.80808, "twoHundredDayAverage": 1.97538, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 135650768, "profitMargins": 0.0, "floatShares": 60664714, "sharesOutstanding": 93705558, "sharesShort": 227571, "sharesShortPriorMonth": 241070, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0023999999, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 0.00149, "shortRatio": 8.52, "shortPercentOfFloat": 0.0027, "impliedSharesOutstanding": 93705558, "bookValue": 0.0670684, "priceToBook": 27.285578, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -46051000, "trailingEps": -0.66, "forwardEps": -0.606, "enterpriseToRevenue": 10.735, "enterpriseToEbitda": -2.725, "52WeekChange": 0.029069781, "SandP52WeekChange": 0.1575526, "quoteType": "EQUITY", "currentPrice": 1.83, "targetHighPrice": 8.0, "targetLowPrice": 2.0, "targetMeanPrice": 5.75, "targetMedianPrice": 6.5, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 60027000, "totalCashPerShare": 0.651, "ebitda": -49771000, "totalDebt": 27029000, "quickRatio": 2.081, "currentRatio": 2.208, "totalRevenue": 12636000, "debtToEquity": 525.447, "revenuePerShare": 0.15, "returnOnAssets": -0.25922, "returnOnEquity": -2.71367, "grossProfits": -30788000, "freeCashflow": -20764000, "operatingCashflow": -41096000, "revenueGrowth": -0.606, "grossMargins": -2.43653, "ebitdaMargins": 0.0, "operatingMargins": -5.23189, "financialCurrency": "EUR", "symbol": "IPHA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "postMarketChangePercent": 1.6393427, "postMarketPrice": 1.86, "postMarketChange": 0.029999971, "regularMarketChange": 0.060000062, "regularMarketDayRange": "1.78 - 1.89", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 203240, "fiftyTwoWeekLowChange": 0.20000005, "fiftyTwoWeekLowChangePercent": 0.12269942, "fiftyTwoWeekRange": "1.63 - 2.63", "fiftyTwoWeekHighChange": -0.8000001, "fiftyTwoWeekHighChangePercent": -0.30418253, "fiftyTwoWeekChangePercent": 2.9069781, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1571319000000, "marketState": "CLOSED", "earningsTimestamp": 1763040600, "earningsTimestampStart": 1763040600, "earningsTimestampEnd": 1763040600, "earningsCallTimestampStart": 1763038800, "earningsCallTimestampEnd": 1763038800, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.66, "epsForward": -0.606, "epsCurrentYear": -0.64467, "priceEpsCurrentYear": -2.8386617, "fiftyDayAverageChange": 0.021920085, "shortName": "Innate Pharma S.A.", "longName": "Innate Pharma S.A.", "corporateActions": [], "postMarketTime": 1769809890, "regularMarketTime": 1769806802, "exchange": "NMS", "messageBoardId": "finmb_426137", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.389834, "regularMarketPrice": 1.83, "fiftyDayAverageChangePercent": 0.012123405, "twoHundredDayAverageChange": -0.1453799, "twoHundredDayAverageChangePercent": -0.07359592, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "displayName": "Innate Pharma", "trailingPegRatio": null, "__fetch_time": "2026-01-31"}]